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To the Editor: 
Baertling and colleagues report an 18 months old previous early preterm child with biochemical 
signs of carbonic anhydrase VA (CAVA) deficiency, later genetically confirmed, and a fatal 
outcome [1]. In the patient, they report concurrent arterial hypertension. The patient received 
early and adequate therapeutic measures which led to rapid normalization of the biochemical 
abnormalities [2]. Despite this, the patient died after developing severe intracranial 
hypertension, brain edema and herniation.  
Authors conclude that “this disease can be fulminant and fatal despite … adequate treatment” 
[1]. While this comment is certainly entirely correct, it is not so clear what caused the fatal 
course in this patient. According to the information provided, the metabolic decompensation 
due to CAVA deficiency was fully resolved after 24 hours. The following clinical course may 
therefore be entirely caused by the arterial hypertension that was present at manifestation 
without any obvious explanation. In our opinion, the uncontrolled arterial hypertension is more 
likely the cause of the fatal course than sequelae from metabolic decompensation. Levels of 
ammonia, blood gases and lactate as reported were still in a range allowing for complete 
correction after the fully adequate treatment that the patient received. Since encephalopathy 
persisted despite this normalization, the possibility of causation due to arterial hypertension 
should be considered. 
It would have been good though to know in more detail about the maximum levels of ammonia 
and lactate, and whether other biochemical hallmarks of CAVA deficiency were present (such 
as hypoglycaemia or ketosis). As well, exact magnitude of arterial hypertension would have 
been interesting for a full understanding. Finally, regarding the identified homozygous deletion 
of the first two exons of the CA5A gene, this mutation clearly destroys the normal gene function 
[2]. Absence of metabolic decompensation in this patient after birth could be the result of the 
early anabolic treatment that he likely received when born preterm at 26 weeks.    
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